Forecasted data for antibacterial medicine sales in Canada indicates a downward trajectory from 2024 to 2028, decreasing from 0.9% to 0.2% of total sales. This trend suggests a diminishing proportion of antibacterial medicine in the pharmaceutical market. As of 2023, the baseline value is not explicitly provided. Year-on-year declines are substantial, reflecting a growing shift away from these medicines. The compound annual growth rate (CAGR) over five years is negative, reinforcing the consistent downward movement.

Future trends to watch for include:

Increased focus on antibiotic resistance could impact sales positively if new solutions are introduced.
Policy changes and public health initiatives aimed at reducing antibiotic use may further decrease sales.
New advancements in antibacterial treatments or the emergence of resistant strains may shift market dynamics.